Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. ADC Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-216.38 Mil. ADC Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $291.50 Mil.
Therefore, ADC Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was -0.74.
The historical rank and industry rank for ADC Therapeutics's Equity-to-Asset or its related term are showing as below:
ADCT'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.87 Med: 0.2 Max: 0.92
Current: -0.74
During the past 10 years, the highest Equity to Asset Ratio of ADC Therapeutics was 0.92. The lowest was -0.87. And the median was 0.20.
ADCT's Equity-to-Asset is ranked worse than 95.13% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs ADCT: -0.74
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
ADC Therapeutics Equity-to-Asset Related Terms
ADC Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for ADC Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADCT vs LFCR, DERM, BGM: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ADC Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADC Therapeutics Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ADC Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where ADC Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
ADC Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADC Therapeutics (ADCT) has a Equity-to-Asset of -0.74 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on ADC Therapeutics and its competitors. According to the industry distribution chart, ADC Therapeutics ranks #958 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 95.1%.
Is ADC Therapeutics' Equity-to-Asset too high?
ADC Therapeutics' current Equity-to-Asset is -0.74. Based on the distribution chart, ADC Therapeutics ranks #958 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ADC Therapeutics has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ADC Therapeutics' Equity-to-Asset compare to LFCR and DERM?
According to the Drug Manufacturers industry distribution chart, ADC Therapeutics ranks #958 out of 1007 companies for Equity-to-Asset. This places ADC Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on ADC Therapeutics and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADC Therapeutics's current Equity-to-Asset is -0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, ADC Therapeutics (ADCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.08, compared to a current price of $1.11 — trading 46.6% below its estimated fair value. The current Equity-to-Asset is -0.74. ADC Therapeutics' overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For ADC Therapeutics (ADCT), the current Equity-to-Asset is -0.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADC Therapeutics (ADCT) Overvalued in 2026?
Based on GuruFocus' analysis, ADC Therapeutics stock appears to be undervalued.
The current stock price of $1.11 is trading 46.6% below its estimated GF Value™ of $2.08.
GuruFocus considers ADC Therapeutics to be Possible Value Trap.
Key valuation signals for ADCT:
Equity-to-Asset: -0.74
GF Value™: $2.08 vs. price of $1.11 (46.6% below fair value)
No single metric tells the full story. See the ADCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
35GF Score
Get the complete analysis for ADCT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADCT has been successfully added to your 
